Last reviewed · How we verify

Gaba International AG — Portfolio Competitive Intelligence Brief

Gaba International AG pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
elmex® gelée elmex® gelée marketed Topical fluoride agent Tooth enamel hydroxyapatite; bacterial glycolytic enzymes Dental/Oral Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. CareQuest Institute for Oral Health · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Hadassah Medical Organization · 1 shared drug class
  4. King Abdulaziz University · 1 shared drug class
  5. Nisreen Ibrahim khan · 1 shared drug class
  6. Procter and Gamble · 1 shared drug class
  7. Technische Universität Dresden · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gaba International AG:

Cite this brief

Drug Landscape (2026). Gaba International AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gaba-international-ag. Accessed 2026-05-16.

Related